
Media & Investor Relations:
Troy Wichterman
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com
LHA Investor Relations
www.lhai.com
2121 Avenue of the Stars
Suite 2970
Los Angeles, CA 90067
Phone: 310-691-7100
Jody Cain: jcain@lhai.com
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com
Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.
Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Aug 05 2021
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene...
- Jul 14 2021Chairman of the Board Raymond W. Cohen Retires After 15 Years of Service
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...
- Jun 15 2021
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...
- May 19 2021
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...
- May 13 2021Achieves record quarterly revenue of $16.8 million, a 39% increase over the prior year and 14% increase over the prior quarter
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...